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Objective: To assess depressive symptom outcomes in a pooled sample of epilepsy 
self‐management randomized controlled trials (RCTs) from the Managing Epilepsy 
Well (MEW) Network integrated research database (MEW DB).
Methods: Five prospective RCTs involving 453 adults with epilepsy compared 
self‐management intervention (n = 232) versus treatment as usual or wait‐list con-
trol outcomes (n = 221). Depression was assessed with the nine‐item Patient Health 
Questionnaire. Other variables included age, gender, race, ethnicity, education, in-
come, marital status, seizure frequency, and quality of life. Follow‐up assessments 
were collapsed into a visit 2 and a visit 3; these were conducted postbaseline.
Results: Mean age was 43.5 years (SD = 12.6), nearly two‐thirds were women, 
and nearly one‐third were African American. Baseline sample characteristics were 
mostly similar in the self‐management intervention group versus controls. At follow‐
up, the self‐management group had a significantly greater reduction in depression 
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1 |  INTRODUCTION
Epilepsy self‐management is an approach that helps people 
with epilepsy learn skills to help them better manage their ep-
ilepsy and its effect on daily life. Three broad areas targeted 
are treatment management, seizure management, and life‐
style management.1‒8 In 2007, the US Centers for Disease 
Control and Prevention (CDC) established the Prevention 
Research Centers’ Managing Epilepsy Well (MEW) Network 
to develop, test, and disseminate epilepsy self‐management 
interventions.3,9
The MEW Network has developed an integrated database 
(MEW DB) that pools data from epilepsy self‐management 
studies to conduct aggregate and secondary analysis.10,11 A 
recent analysis from the MEW DB that examined correlates 
of depressive symptoms assessed with the nine‐item Patient 
Health Questionnaire (PHQ‐9) found more severe depres-
sion in those with poorly controlled seizures.12 Other studies 
demonstrate that depression in epilepsy is common and asso-
ciated with powerful negative effects including worse seizure 
control, poor quality of life, and premature mortality due to 
suicide.13‒15
A recent literature review of psychological treatments 
in people with epilepsy found that one‐third of patients re-
ceiving cognitive behavioral therapy (CBT) interventions, 
compared to 10% of controls, could be considered “reliably 
improved.”16 However, given the great number of under-
treated people with epilepsy who also have depression, the 
development of additional psychological approaches, in-
cluding alternatives to CBT, is warranted. There is consid-
erable conceptual overlap among psychological approaches 
intended to help improve health outcomes among people with 
epilepsy. For example, both CBT and epilepsy self‐manage-
ment interventions include a focus on improving emotional 
regulation and the development of personal coping strategies 
that address solving current problems.16,17 Although there is 
still a relative paucity of randomized controlled trials (RCTs) 
focused on epilepsy self‐management interventions,18 the 
CDC‐supported MEW Network website describes evi-
dence‐based epilepsy self‐management intervention such 
as the HOBSCOTCH (Home‐Based Self‐Management and 
Cognitive Training Changes Lives) approach intended to 
improve cognitive problems in adults with epilepsy and the 
TIME (Targeted Self‐Management for Epilepsy and Mental 
Illness) approach targeting adults with epilepsy and comorbid 
mental health conditions, as well as emerging research for 
self‐management interventions that are still in development.8 
Given the MEW Network's focus on depression comorbidity, 
a number of sites conducting RCTs in epilepsy self‐manage-
ment interventions have the PHQ‐9 as a primary or second-
ary outcome. All MEW Network RCTs have used a treatment 
as usual or wait‐list comparison control, providing relative 
homogeneity in study design.
Given the critical need for managing depressive symp-
toms in epilepsy and the limited benefit with standardized 
psychological approaches such as CBT,17 this aggregate anal-
ysis was conducted to address the broad question of whether 
a curriculum‐driven epilepsy self‐management intervention 
can improve depression outcomes in people with epilepsy. 
compared to controls at visit 2 (P < .0001) and visit 3 (P = .0002). Quality of life 
also significantly improved in the self‐management group at visit 2 (P = .001) and 
visit 3 (P = .005).
Significance: Aggregate MEW DB analysis of five RCTs found depressive symptom 
severity and quality of life significantly improved in individuals randomized to self‐
management intervention versus controls. Evidence‐based epilepsy self‐management 
programs should be made more broadly available in neurology practices.
K E Y W O R D S
depression, epilepsy, quality of life, seizures, self‐management
Key Points
• This report analyzed pooled data from five self‐
management randomized controlled trials from 
the Managing Epilepsy Well Network
• The sample of 453 adults had a mean age of 
43.5  years, nearly two‐thirds were women, and 
nearly one‐third were African American
• At follow‐up, self‐management intervention pa-
tients experienced significantly reduced depres-
sive symptoms compared to controls
• Evidence‐based epilepsy self‐management pro-
grams should be made more broadly available in 
neurology practices
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This is a first‐ever evaluation of the MEW DB longitudinal 
data to examine depressive symptom severity outcomes in 
a pooled sample of epilepsy self‐management intervention 
RCTs. We hypothesized that individuals randomized to a 
self‐management intervention would have greater reduc-
tion in depressive symptom severity over time compared to 
controls.
2 |  MATERIALS AND METHODS
2.1 | Overview
This analysis of longitudinal data included 453 adults 
with epilepsy enrolled in five MEW Network prospec-
tive randomized controlled epilepsy self‐management in-
tervention trials. Details describing the MEW Network, 
including data harmonization, have been described 
elsewhere.9 The aggregate data were derived from indi-
vidual MEW Network research studies with approval by 
the institutional review board of University Hospitals 
Cleveland Medical Center. Only RCTs that included use 
of the PHQ‐9 administered in a longitudinal manner were 
included in this analysis. The deidentified data used for 
the analysis were obtained from the HOBSCOTCH trial 
at Dartmouth‐Hitchcock Medical Center,5 the PACES 
(Program of Active Consumer Engagement in Self‐
Management) trial from the University of Washington, the 
FOCUS (Figure Out the Problem, Observe Your Routine, 
Connect Your Observations and Choose a Change Goal, 
Undertake a Change Strategy, and Study the Results) 
trial from the University of Michigan, and the TIME and 
SMART (Self‐Management for People With Epilepsy and 
a History of Negative Health Events) trials from Case 
Western Reserve University. All RCT participants were 
adults at least 18 years of age or older. All studies had a 
self‐reported diagnosis of epilepsy except where noted in 
the specific study descriptions below. None of the studies 
required a depression diagnosis or a specific depression 
severity threshold for study inclusion. All study partici-
pants expressed informed consent for participation in the 
respective studies.
2.2 | Description of each study
2.2.1 | HOBSCOTCH5
Study design: Prospective RCT.
Inclusion criteria: Adult patients with a diagnosis of 
epilepsy (confirmed by clinical evidence or ancillary stud-
ies). Epilepsy was controlled or uncontrolled but without 
severe intellectual disability. Participants had subjective 
memory complaints defined as scores of  ≤7 on a subset 
of cognition questions of the Quality of Life in Epilepsy 
(QOLIE‐31). (Subset questions were normalized to a score 
between 0 and 10.)
Sample: Sixty‐six adults, age = 18‐65 years.
Description of the intervention: Self‐management in-
tervention delivered one‐on‐one, primarily by telephone. 
Combines problem‐solving therapy with memory strategies.19
Intervention comparator: Twenty‐four–week wait‐list 
control.
Key outcomes: Quality of life and objective memory. 
Depressive symptom severity using the PHQ‐9 was assessed 
as a covariate. In the original study primary outcome report, 
depression scores among the treatment cohorts showed im-
provement but did not reach statistical significance.5
Total study duration, timing of research assessments: 
Twenty‐four–week study, assessments at baseline, 8‐10 weeks 
(visit 2), and 24 weeks (visit 3).
2.2.2 | PACES6
Study design: Prospective RCT.
Inclusion criteria: Epilepsy without substantive cogni-
tive impairment. Inclusion criteria also included having ac-
tive (seizure within the past 6 months) and chronic (at least 
6 months since diagnosis) epilepsy.
Sample: Two hundred eighty‐three adults, age ≥ 18 years.
Description of the intervention: In‐person, 8‐week med-
ical and psychosocial self‐management group intervention 
that is focused on improving medical and psychosocial man-
agement, problem‐solving, and behavioral activation.
Intervention comparator: Treatment as usual.
Key outcomes: The primary study outcomes were epilepsy 
self‐efficacy, epilepsy self‐management, and goal attainment. 
Depression (PHQ‐9) was assessed as a secondary outcome. In 
the original study primary outcome report, depressive symp-
toms were significantly improved at program completion.6
Total study duration, timing of research assessments: 
Twenty‐four–week study. Research assessments were con-
ducted at baseline (start of program), immediately postinter-
vention (8 weeks/visit 2), and at 24 weeks postprogram (visit 
3).
2.2.3 | FOCUS
Study design: Prospective RCT. Study outcomes have not 
been published.
Inclusion criteria: Adults with epilepsy for at least 1 year, 
taking antiepileptic medication daily and being able to iden-
tify a support person willing to participate.
Sample: One hundred thirty adults, age ≥ 21 years.
Description of the intervention: Eight‐week hybrid in‐
person workshop and telephone coaching program that de-
veloped self‐regulation skills in both adults with epilepsy and 
a key friend or family member who provides support.
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Intervention comparator: Control group members re-
ceived written patient education materials on topics known 
to impact quality of life for people with epilepsy (eg, sleep 
and stress) and information on regional and national epilepsy 
resources.
Key outcomes: The primary study outcome was the 31‐
item QOLIE‐31. Depression, using the PHQ‐9, was assessed 
as a secondary outcome. In the original study analysis, no 
significant differences between the intervention and control 
groups were found in pre‐post changes in depression.
Total study duration, timing of research assessments: 
Forty‐week study. Active intervention period was 10 weeks. 
Research assessments (telephone surveys) were conducted 
at baseline (prior to start of program) and approximately 
40 weeks from baseline (visit 2).
2.2.4 | SMART20
Study design: Prospective 24‐week RCT. The RCT was fol-
lowed by a 12‐month extension follow‐up phase.
Inclusion criteria: Epilepsy diagnosis and occurrence of 
a negative health event (NHE) defined as at least one seizure, 
emergency room visit, hospitalization, or self‐harm attempt 
within the past 6 months.
Sample: One hundred twenty adults, age ≥ 18 years.
Description of the intervention: Remotely delivered (Web 
or telephone) nurse + peer educator group‐format self‐man-
agement intervention focused on managing seizures, stress, 
and life‐style to optimize health functioning.
Intervention comparator: Twenty‐four–week wait‐list 
control.
Key outcomes: The primary study outcome was change in 
NHE counts from baseline to follow‐up assessments at week 
12 and week 24. Depression using the PHQ‐9 was assessed 
as a secondary outcome. In the original study primary out-
come report, depression scores were significantly improved 
in SMART versus controls.20
Total study duration, timing of research assessments: Only 
the 24‐week RCT data were used for this analysis. Research 
assessments were done at baseline, 10 weeks (visit 2), and 
24 weeks (visit 3).
2.2.5 | TIME7
Study design: Prospective RCT.
Inclusion criteria: Epilepsy and the presence of comorbid 
serious mental illness defined as schizophrenia, bipolar dis-
order, or major depression. Depressive symptoms were not 
required for inclusion.
Sample size, mean age: Forty‐four adults, age ≥ 18 years.
Description of the intervention: In‐person, nurse and peer 
educator led group‐format intervention to improve both mood 
and epilepsy outcomes.
Intervention comparator: Treatment as usual.
Key outcomes: The primary study outcome was depres-
sive symptom severity assessed with the Montgomery‐Asberg 
Depression Rating Scale.21 Depressive symptoms using the 
PHQ‐9 were assessed as a secondary outcome. In the original 
study primary outcome report, depression scores were signifi-
cantly improved in TIME versus controls.7
Total study duration, timing of research assessments: 
Sixteen‐week study. Research assessments were conducted at 
baseline, 12 weeks (visit 2), and 16 weeks (visit 3) follow‐up.
2.3 | Measures
Variables assessed in the studies included age, gender, race, 
ethnicity, educational level, income, marital/relationship sta-
tus, seizure frequency, and two standardized measures that 
evaluated depressive symptom severity and epilepsy‐related 
quality of life.
2.4 | Depressive symptom severity
Depressive symptom severity was assessed using the PHQ‐9, 
a widely used and validated self‐rated depression scale.22 
The PHQ‐9 incorporates Diagnostic and Statistical Manual 
of Mental Disorders diagnostic criteria, with scores rang-
ing from 0 to 27. Items are scored on a 0‐3 continuum, with 
higher scores indicating worse depressive symptom severity. 
Based on total PHQ‐9 scores, there are several well‐docu-
mented groups of depressive severity: 1‐4 = minimal depres-
sion, 5‐9 = mild depression, 10‐14 = moderate depression, 
15‐19 = moderately severe depression, and 20‐27 = severe 
depression.
2.5 | Quality of life
Quality of life was assessed with an adapted version of the 
10‐item QOLIE (QOLIE‐10) instrument, a self‐administered 
questionnaire developed from the original QOLIE‐89.23 The 
QOLIE‐10 has good test‐retest reliability and correlates well 
with longer versions of this instrument.24 A 31‐item version 
of the QOLIE (QOLIE‐31) and a patient‐weighted version 
of the QOLIE (QOLIE‐P) include the same 10 questions 
but have slightly different scoring ranges (1‐6, 1‐4) on three 
items. Given the slightly different versions of the questions 
across studies in the MEW DB, scores were calibrated to 
yield a total possible score range of 1‐5, with lower scores 
indicating better quality of life and fewer problems related 
to epilepsy.
2.6 | Data cleaning and harmonization
All MEW‐DB data are linked following a study protocol and a 
data dictionary with labels for each variable. Study datasets were 
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first evaluated to confirm that data dictionary variables clearly 
delineated dataset content and assessment timing. As has been 
described elsewhere, data mapping was done to allow integra-
tion between study‐specific variables and the MEW common 
terminology system, and involved reconciling differences in 
both data values and interval values used to categorize the data 
elements.10 For seizure frequency, we “prorated” counts based 
upon the time interval being assessed to derive a past 30‐day 
seizure frequency. For example, if the original study's seizure 
count data were derived from a 90‐day period, we would divide 
the count by 3 to calculate a 30‐day seizure frequency. For the 
longitudinal component of the analysis, given that our intent 
was to evaluate the trajectories of depressive symptom severity 
over time, we collapsed data collection follow‐up time‐points 
into two groups of follow‐up assessments. Visit 2 was the first 
assessment conducted after completion of the self‐management 
intervention, and visit 3 was the second assessment done after 










Age, mean (SD) 43.5 (12.6) 44.5 (12.5) 42.4 (12.6) .0662a
Female, n (%) 288 (63.7%) 147 (63.6%) 141 (63.8%) .5893b
Race, n (%)
White 232 (59.9%) 110 (58.5%) 122 (61.3%) .6434b
Black/African American 123 (31.8%) 60 (31.9%) 63 (31.7%)
Other 32 (8.3%) 18 (9.6%) 14 (7%)
Ethnicity, n (%)
Not Hispanic 356 (92.7%) 170 (91.9%) 186 (93.5%) .5530b
Hispanic 28 (7.3%) 15 (8.1%) 13 (6.5%)
Education, n (%)
High school or less 141 (31.4%) 73 (31.9%) 68 (30.9%) .8250b
At least some college 308 (68.6%) 156 (68.1%) 152 (69.1%)
Income, n (%)
<$25K 227 (69.6%) 114(70.8%) 113(68.5%) .8273b
$25‐50K 40 (12.3%) 20 (12.4%) 20 (12.1%)
>$50K 59 (18.1%) 27 (16.8%) 32 (19.4%)
Marital status, n (%)
Married or partnered 73 (29.7%) 46 (38.0%) 27 (21.6%) .0048b
Other 173 (70.3%) 75(62.0%) 98(78.4%)  
30‐day seizure frequency, 
mean (SD)
4.5 (21.0) 4.4 (24.3) 4.5 (16.8) .4576c
QOLIE‐10, mean (SD) 2.9 (0.9) 2.9 (0.9) 2.8 (0.8) .6255a
PHQ‐9, mean (SD) 9.2 (6.5) 8.9 (6) 9.4 (6.9) .4635b
Minimal depression, n (%) 176 (20.1%) 93 (20.0%) 83 (20.2%)
Mild depression, n (%) 288 (32.8%) 172 (37.0%) 116 (28.2%)
Moderate depression, n (%) 195 (22.2%) 105 (22.6%) 90 (21.8%)
Moderately severe depres-
sion, n (%)
134 (15.3%) 70 (15.1%) 62 (15.5%)
Severe depression, n (%) 84 (9.6%) 25 (5.4%) 59 (14.3%)
Note: Minimal depression: PHQ‐9 total score = 1‐4; mild depression: PHQ‐9 total score = 5‐9; moderate 
depression: PHQ‐9 total score = 10‐14; moderately severe depression: PHQ‐9 total score = 15‐19; severe 
depression: PHQ‐9 total score = 20‐27.




cMann‐Whitney U test. 
T A B L E  1  Baseline demographic 
and clinical variables among people with 
epilepsy randomized to self‐management 
intervention compared to controls
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8‐12 weeks after baseline (except for FOCUS, which had a sin-
gle follow‐up visit at 36‐40 weeks), whereas visit 3 was con-
ducted 16‐36 weeks after baseline. Because the FOCUS study 
had only one follow‐up assessment, the follow‐up visit was con-
sidered the visit 2 data collection point.
2.7 | Data analysis
Statistical analysis was performed using SAS 9.4 (SAS 
Institute). Descriptive analyses characterized the base-
line sample and examined change over time in PHQ‐9. 
Longitudinal mixed models from baseline to visit 2 and visit 
3 were conducted. A type I error rate of 0.05 was used. To 
validate the pooled longitudinal PHQ‐9 total findings and 
confirm that they were not contingent upon a single study, 
a series of t tests for the change from baseline to visit 2 and 
change from baseline to visit 3 were conducted by leaving 
out each one of the studies, one at a time. To examine the 
relationship between variables at baseline and change in 
PHQ‐9 over time, mixed model analyses were conducted in 
the combined group of intervention + controls. Given the 
known relationship between quality of life and depressive 
symptom severity, the association between a 1‐point change 
in QOLIE‐10 and PHQ‐9 was also quantified.
3 |  RESULTS
3.1 | Baseline sample
Table 1 shows characteristics of all individuals with epilepsy 
in the pooled sample (N = 453), as well as by treatment status: 
self‐management intervention group (n = 232) versus controls 
(n = 221). Mean age of the combined sample was 43.5 years 
(SD = 12.6), with nearly two‐thirds being women and nearly 
one‐third being African American (Table 1). Although the ma-
jority of the combined sample had some education beyond high 
school (68.6%, n = 308), the majority were living in restricted 
financial circumstances, with 69.6% (n = 227) having an an-
nual income below US $25 000. Most demographic and clini-
cal characteristics were similar between the intervention and 
control groups. Only marital status was statistically different 
between the intervention and control groups, with slightly more 
individuals in the intervention group (38%, n = 46) versus con-
trols (21.6%, n = 27) being married or partnered.
3.2 | Change in depressive symptom severity 
over time
Tables 2 and 3 show the change over time in total unadjusted 
mean PHQ‐9 scores in the self‐management intervention ver-
sus control groups and in each of the five RCTs separately. As 
seen in Figure 1, in the pooled sample over the three assessment 
time‐points, individuals randomized to self‐management inter-
vention had a significantly greater reduction in total depressive 
symptom severity compared to controls at visit 2 (P < .0001) 
and at visit 3 (P = .0002). As noted in Table 4, the validation 
exercise in which each study was omitted one at a time and 
the remainder evaluated for change over time showed largely 
similar findings to the pooled analysis with respect to change 
in PHQ‐9 totals between baseline and visits 2 and 3. In addi-
tion to examination of PHQ‐9 as a continuous variable, we also 
examined the clinically relevant change in the sample propor-
tion in the self‐management intervention group versus the con-
trol group who improved from having a depressive symptom 
severity score of moderately depressed (PHQ‐9 score ≥ 10). 
There was no statistically significant difference in the percent-
age of the intervention group (41.3%) versus control group 
(44.2%) that had a PHQ‐9 score of ≥10 at baseline (P = .537). 
However, at visit 3, the percentages were significantly different 
(P < .001), with only 24.8% of the intervention group having a 
PHQ‐9 score ≥ 10 versus 47.1% of controls.
3.3 | Association between demographic/
clinical variables and change in depressive 
symptom severity
As noted in Table 5, quality of life was also significantly 
improved in self‐management intervention versus controls 
at visit 2 (P =  .001) and visit 3 (P =  .005). Mixed‐model 
analyses are shown in Table 6. For the combined sample, 
treatment assignment, visit time‐point, educational level, 
and quality of life at baseline were all significantly associ-
ated with change in PHQ‐9. Individuals randomized to the 





Visit Mean (SD) Mean (SD) Mean (SD)
Baseline, N = 453 9.2 (6.5) 8.9 (6) 9.4 (6.9) .4635
Visit 2, n  = 398 8.5 (6.1) 7.2 (5.4) 9.7 (6.5) <.0001
Visit 3, n = 255 8.3 (6.5) 6.9 (6.1) 9.9 (6.6) .0002
Abbreviation: PHQ‐9, nine‐item Patient Health Questionnaire.
T A B L E  2  Change in PHQ‐9 total 
score over time in people with epilepsy 
randomized to self‐management versus 
controls
   | 1927SAJATOVIC eT Al.
time as evidenced by the significant treatment‐time inter-
action. Individuals with higher educational levels (at least 
some college) had lower endpoint PHQ‐9 scores than those 
with lower education, with an average difference of 1.87 
(SD = 0.70). In examining only the sample of individu-
als randomized to control, lower education was associated 
with less improvement in depressive symptoms (P = .033), 
whereas educational level was not significantly associated 
with change in depressive symptoms in the intervention 
group (data not shown). The relationship between quality 
of life and depression was significant, and a 4.9 increase 
in PHQ‐9 (worse depression) corresponded to a one‐point 
increase in QOLIE‐10 (worse quality of life).
4 |  DISCUSSION
These analyses, taking advantage of a novel aggregate data-
set from a CDC‐sponsored research collaborative,8 investi-
gated the relationship between participation in an epilepsy 
self‐management intervention and depressive symptom se-
verity outcomes over time. Analyses from five RCTs that all 
used a prospective design comparing self‐management inter-
vention versus treatment as usual or waitlist control suggests 
that depressive symptom severity is significantly reduced in 
people with epilepsy who participate in a self‐management 
intervention program. Given the known association of de-
pression with poor outcomes among people with epilepsy,1‒8 
the findings have important clinical implications along sev-
eral dimensions.
A key clinical implication is the potential utility of self‐





Study Visit (week)b Mean (SD) Mean (SD) Mean (SD)
FOCUS‐RCT Baseline 7.6 (6.1) 7.8 (5.9) 7.5 (6.4)  
Visit 2 (36‐40) 7.0 (5.4) 6.9 (5.7) 7.2 (5.1) .4051
HOBSCOTCH Baseline 9.4 (5.9) 9.6 (5.8) 9.2 (6.3)  
Visit 2 (8‐10) 8.8 (5.2) 7.8 (4.4) 10.5 (5.9) .3395
Visit 3 (24) 8.1 (5.9) 7.1 (5.4) 9.6 (6.4) .1586
PACES Baseline 8.4 (6.1) 8.2 (5.8) 8.5 (6.3)  
Visit 2 (12) 7.2 (5.4) 5.2 (4) 8.8 (5.9) .0125
Visit 3 (36) 7 (6.2) 6.3 (6.8) 7.5 (5.5) .8277
SMART Baseline 10.7 (7.2) 10 (6.6) 11.5 (7.8)  
Visit 2 (12) 10 (7.1) 7.8 (6.2) 11.9 (7.4) .0050
Visit 3 (24) 9.1 (7) 7.3 (6.6) 10.8 (7) .1080
TIME Baseline 10.7 (5.5) 9.5 (5.3) 11.9 (5.6)  
Visit 2 (12) 11.2 (5.6) 9.2 (5) 13.2 (5.7) .1559
Visit 3 (16) 9.5 (6.4) 6.4 (4.4) 12.9 (6.6) .0131
Abbreviations: PHQ‐9, nine‐item Patient Health Questionnaire; RCT, randomized controlled trial.
aChange from baseline between intervention group versus control. 
bVisits 2 and 3 were follow‐up visits conducted after the completion of the epilepsy self‐management program 
was completed. Visit 2 was conducted 8‐12 weeks after baseline for all except FOCUS (which had a single 
follow‐up visit conducted at 36‐40 weeks). For all studies except FOCUS, which only had one follow‐up time‐
point, visit 3 was conducted 16‐36 weeks after baseline. 
T A B L E  3  Change in PHQ‐9 total 
scores over time in five epilepsy self‐
management randomized controlled trials
F I G U R E  1  Total mean score on nine‐item Patient Health 
Questionnaire (PHQ‐9) over time in self‐management randomized 
participants versus controls. P value at visit 2 < .0001, P value at visit 
3 = .0002
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people with epilepsy. A recent literature review16 found 
that psychological treatments that encompass a broad 
range of nonpharmacological interventions for individuals, 
families, or groups have strong evidence for improving de-
pressive symptoms in epilepsy. However, this review only 
identified one study that specifically investigated depres-
sion outcomes for a self‐management intervention.6 Our 
analysis provides additional evidence that self‐manage-
ment support can consistently improve depressive symptom 
severity in epilepsy. In addition to improving depressive 
outcomes, self‐management support in this pooled analy-
sis was associated with improved quality of life for people 
with epilepsy.
A recent literature review by Luedke and colleagues17 that 
specifically evaluated epilepsy self‐management interven-
tions suggested that changes in knowledge about epilepsy as 
well as improvement in self‐efficacy, self‐management skills, 
and lifestyle modification might explain, at least in part, the 
reduction in depressive symptoms that may be observed in 












−0.6 (5) −1.5 (5) 0.3 (4.9) .0003
Diff base-
line vs V3





−0.7 (5) −1.7 (5.1) 0.3 (4.8) .0004
Diff base-
line vs V3
−1.2 (5.9) −2.2 (5.7) −0.4 (6) .0305
FOCUS omitted Diff base-
line vs V2
−0.5 (5) −1.7 (4.8) 0.6 (4.9) .0001
Diff base-
line vs V3
−1.2 (5.8) −2.1 (5.5) −0.2 (6) .0120
TIME omitted Diff base-
line vs V2
−0.7 (4.9) −1.6 (4.9) 0.1 (4.8) .0009
Diff base-
line vs V3
−1.3 (5.8) −2 (5.5) −0.6 (6) .0824
PACES omitted Diff base-
line vs V2
−0.5 (5.3) −1.4 (5.2) 0.4 (5.2) .0026
Diff base-
line vs V3
−1.2 (6.2) −2.4 (5.7) 0.2 (6.5) .0042
SMART omitted Diff base-
line vs V2
−0.4 (4.7) −1.1 (4.8) 0.3 (4.6) .0157
Diff base-
line vs V3
−0.8 (5.2) −1.7 (5.2) 0 (5.1) .0476
Abbreviations: Diff, difference; PHQ‐9, nine‐item Patient Health Questionnaire; V, visit.
at test. 
T A B L E  4  Validation exercise to 
examine change over time difference in 
PHQ‐9 total scores after sequential omission 






Visit Mean (SD) Mean (SD) Mean (SD)
Baseline, N = 453 2.9 (0.9) 2.9 (0.9) 2.8 (0.8) .6255
Visit 2, n = 398 2.7 (0.8) 2.6 (0.9) 2.9 (0.8) .0017
Visit 3, n = 255 2.6 (0.9) 2.5 (0.9) 2.8 (0.8) .0045
Abbreviation: QOLIE‐10, 10‐item Quality of Life in Epilepsy.
T A B L E  5  QOLIE‐10 mean 
scores over time in people with epilepsy 
randomized to self‐management versus 
controls
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programs. It is possible that the holistic/whole‐person focus, 
which is an intrinsic element of this approach, can help in-
dividuals regulate their emotions and make healthy lifestyle 
changes that enhance mood and well‐being. Supportive inter-
actions with self‐management interventionists and the group 
format in some of the programs might also help reduce social 
isolation and loneliness experienced by some people with 
epilepsy.
An important feature of the MEW Network applied re-
search agenda is collaboration with community stakehold-
ers, including people with epilepsy, their families, public 
service agencies, clinicians, and healthcare entities, to scale 
up and disseminate epilepsy self‐management approaches.7,8 
Consistent with this science‐to‐service mission, there are a 
variety of opportunities for clinicians, patients, and families 
to access MEW Network programs and tools (https ://manag 
ingep ileps ywell.org/). Another key element of initiating care 
and support for people with epilepsy who have depression is 
early screening and identification. The American Academy 
of Neurology includes screening for psychiatric and behav-
ioral disorders at each epilepsy care encounter as a quality 
measure for the delivery of optimal care and better outcomes 
for individuals with epilepsy.25 Effective screening can iden-
tify individuals who might benefit from self‐management 
support or other treatments to manage their depression.
An additional clinical implication of our findings relates 
to the observed trajectory of depression severity in patients 
with epilepsy who did not receive self‐management inter-
vention. In the aggregate data, depression generally did not 
improve over time. It is possible that the lack of change could 
have been related to none of the studies being conducted 
under blinded conditions, and this may have negatively bi-
ased outcomes, as people who do not expect to get treatment 
may not get better. However, the extant literature in chronic 
diseases generally suggests that depression also tends to be 
chronic for many individuals, especially if untreated.26,27 Our 
analysis found that individuals with epilepsy who have less 
education may be particularly likely to have poor outcomes in 
the usual treatment/wait‐list trajectory; this subgroup might 
benefit from a more intensive and perhaps less complex form 
of self‐management intervention. We did not see that base-
line level of education was associated with a difference in 
depression outcomes among individuals randomized to self‐
management intervention. This might suggest that self‐man-
agement intervention could, at least in part, level the playing 
field or minimize health disparities that might otherwise 
occur among less educated people with epilepsy.
Our results also highlight the close relationship between 
depressive symptom severity and quality of life (higher/
worse depression severity = lower quality of life).28 The rele-
vance of depressive symptoms to quality of life and other out-
comes in people with epilepsy is substantial, and the MEW 
Network has prioritized a focus on mental health comorbidity 
with a particular emphasis on depression.9,29 A non–MEW 
Network study that analyzed individuals with poorly con-
trolled epilepsy found that, in order of large to small magni-
tude, depression, low self‐mastery, anxiety, stigma, medical 
and psychiatric comorbidity, poor medication adherence, and 
more frequent seizures were associated with worse quality 
of life.30
This analysis has a number of limitations, including 
the inherent difficulty in interpreting aggregate outcomes 
from studies that were conducted in different settings 
with different eligibility criteria. None of the studies re-
quired a depression diagnosis or a specific threshold of 
depressive symptom severity as part of inclusion criteria, 
and the PHQ‐9 is a depression severity instrument that is 
not specific to epilepsy, in contrast to the epilepsy‐spe-
cific Neurological Disorders Depression Inventory for 
Epilepsy.31 Calibration needed to harmonize QOLIE data 
may not have the same validity as the original standard-
ized scale. Studies had follow‐up time frequency and 
durations that were not identical, and the process of har-
monizing data from visits for the second and third time‐
point follow‐up may have minimized important elements 
of when depression may or may not change over time in 
people with epilepsy. The control group in our pooled data-
set analysis included individuals with epilepsy who were 
randomized to treatment as usual and those who were ran-
domized to wait‐list control, which may have introduced 
variability to the control group. However, strengths of the 
data include the relatively large sample, representation of 
minorities and people with frequent seizures, similarity of 
T A B L E  6  Mixed‐model analysis of the association of baseline 
demographic and clinical variables with PHQ‐9 total score over time in 
the combined control + intervention group
Variable effect Num DF Den DF F Pr > F
Treatment 1 247 20.39 <.0001
Visit 2 247 3.83 .0231
Treatment × visit 2 247 3.05 .0490
Age 1 247 0.00 .9784
Gender 2 247 0.16 .8536
Race 2 247 2.82 .0613
Ethnicity 1 247 0.07 .7928
Education 1 247 7.23 .0076
Income 2 247 0.53 .5874
Marital status 1 247 0.18 .6711
Seizure frequency 1 247 1.26 .2631
QOLIE‐10 1 247 157.10 <.0001
Abbreviations: Den DF, denominator of degrees of freedom; F, F statistic as-
sociated with the given source; Num DF, number of degrees of freedom; PHQ‐9, 
nine‐item Patient Health Questionnaire; Pr > F, P value associated with the F 
statistic of a given source; QOLIE‐10, Quality of Life in Epilepsy.
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the demographic and clinical variables among individuals 
randomized to intervention versus control, and a validation 
exercise conducted as part of the analysis. Additionally, 
the PHQ‐9 has been selected as an indicator of depression 
quality of care by the National Quality Forum32 and has 
been widely used in studies of patients with epilepsy.33
In conclusion, epilepsy self‐management interventions 
generally address a variety of aspects of helping people 
with epilepsy learn to manage and cope with this common 
neurological condition. Aggregate randomized controlled 
trial findings from a national US epilepsy self‐manage-
ment research collaborative suggest that both depressive 
symptom severity and quality of life improve with epilepsy 
self‐management approaches. Making self‐management in-
terventions more broadly available to people with epilepsy 
who have depression could potentially improve health gen-
erally and minimize the likelihood of complications related 
to epilepsy.
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